bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 5 from Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment
Authors: Evgin Laura , Huff Amanda L. , Kottke Timothy , Thompson Jill , Molan Amy M. , Driscoll Christopher B. , Schuelke Matthew , Shim Kevin G. , Wongthida Phonphimon , Ilett Elizabeth J. , Smith Karen Kaluza , Harris Reuben S. , Coffey Matt , Pulido Jose S. , Pandha Hardev , Selby Peter J. , Harrington Kevin J. , Melcher Alan , Vile Richard G.
Published: April 2023

Suppl Fig 5
Supplementary Figure 2 from Alternative Variants of Human HYDIN Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity
Authors: Laske Karoline , Shebzukhov Yuriy V. , Grosse-Hovest Ludger , Kuprash Dmitry V. , Khlgatian Svetlana V. , Koroleva Ekaterina P. , Sazykin Alexey Y. , Penkov Dmitry N. , Belousov Pavel V. , Stevanović Stefan , Vass Verona , Walter Steffen , Eisel David , Schmid-Horch Barbara D. , Nedospasov Sergei A. , Rammensee Hans-Georg , Gouttefangeas Cécile
Published: April 2023

PDF - 453KB, Supplementary Figure 2: Mapping of major immunogenic region of MO-TES391.
Supplementary Figure 3 from Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment
Authors: Evgin Laura , Huff Amanda L. , Kottke Timothy , Thompson Jill , Molan Amy M. , Driscoll Christopher B. , Schuelke Matthew , Shim Kevin G. , Wongthida Phonphimon , Ilett Elizabeth J. , Smith Karen Kaluza , Harris Reuben S. , Coffey Matt , Pulido Jose S. , Pandha Hardev , Selby Peter J. , Harrington Kevin J. , Melcher Alan , Vile Richard G.
Published: April 2023

Suppl Fig 3
Supplementary Methods, Figure Legend from Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo
Authors: Lanitis Evripidis , Poussin Mathilde , Klattenhoff Alex W. , Song Degang , Sandaltzopoulos Raphael , June Carl H. , Powell Daniel J.
Published: April 2023

PDF file - 159K
Supplementary Figure 2 from Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo
Authors: Lanitis Evripidis , Poussin Mathilde , Klattenhoff Alex W. , Song Degang , Sandaltzopoulos Raphael , June Carl H. , Powell Daniel J.
Published: April 2023

PDF file - 1301K, Figure S2. Absence of degranulation by CD19-28z CART cells in response to tumor cells expressing mesothelin or FRa or both. CD19-28z CART cells were cultured with the indicated antigen-negative tumor cells or tumor cells expressing FRa or mesothelin, or both antigens for 5 h while being stained by an anti-CD107a,b antibody conjugated with FITC. After incubation, T cells were stained for CD8 and CD69 and analyzed by flow cytometry.
Supplementary Figure 1 from Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo
Authors: Lanitis Evripidis , Poussin Mathilde , Klattenhoff Alex W. , Song Degang , Sandaltzopoulos Raphael , June Carl H. , Powell Daniel J.
Published: April 2023

PDF file - 1125K, Figure S1. Correlated scFv and GFP transgene expression following F-28 CAR transduction. T cells were lentivirally transduced to express the costimulatory F-28 CAR and 5 days later were stained for surface scFv using biotinylated protein-L followed by SA-APC. Transduction efficiency was also monitored using GFP transgene expression. Transduction efficiencies are indicated with the percentage of CAR expression of the transduced populations. Coordinate expression of surface scFv and GFP was observed in all experiments.
Supplemental Figures 1 through 3 from Correlation of PD-L1 Surface Expression on Leukemia Cells with the Ratio of PD-L1 mRNA Variants and with Electrophoretic Mobility
Authors: Brodská Barbora , Otevřelová Petra , Kuželová Kateřina
Published: April 2023

Figure S1 Examples of flow-cytometry dotplots Figure S2 Immunofluorescence staining of PD-L1 Figure S3 Correlation of individual mRNA versions
Suppl fig 4 from Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing
Authors: Brandsma Arianne M. , ten Broeke Toine , Nederend Maaike , Meulenbroek Laura A.P.M. , van Tetering Geert , Meyer Saskia , Jansen J.H. Marco , Beltrán Buitrago M. Alejandra , Nagelkerke Sietse Q. , Németh István , Ubink Ruud , Rouwendal Gerard , Lohse Stefan , Valerius Thomas , Leusen Jeanette H.W. , Boross Peter
Published: April 2023

Cetuximab inhibits IgA2-EGFR-induced cytotoxicity by purified PMNs. PMNs were isolated by Ficoll/Histopaque separation and used for ADCC assay at E:T=40:1 against A431-HER2 cells. MAbs were mixed at a 1:1 ratio and each single mAb was used at the indicated concentration (Mean {plus minus} SD; ***: p<0.001; **: p<0.01; Student's t-test).
Supplementary Figure 4 from Retuning of Mouse NK Cells after Interference with MHC Class I Sensing Adjusts Self-Tolerance but Preserves Anticancer Response
Authors: Wagner Arnika Kathleen , Wickström Stina Linnea , Tallerico Rossana , Salam Sadia , Lakshmikanth Tadepally , Brauner Hanna , Höglund Petter , Carbone Ennio , Johansson Maria Helena , Kärre Klas
Published: April 2023

Supplementary Figure 4. Gating strategy used in responsiveness analysis (results shown in Figure 2).
Suppl fig 1 from Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing
Authors: Brandsma Arianne M. , ten Broeke Toine , Nederend Maaike , Meulenbroek Laura A.P.M. , van Tetering Geert , Meyer Saskia , Jansen J.H. Marco , Beltrán Buitrago M. Alejandra , Nagelkerke Sietse Q. , Németh István , Ubink Ruud , Rouwendal Gerard , Lohse Stefan , Valerius Thomas , Leusen Jeanette H.W. , Boross Peter
Published: April 2023

Leukocyte-mediated cytotoxicity with IgG and IgA. 4 hour 51Cr-release assay by leukocytes using (A) A431 cells and (B) SK-BR-3 cells and 1 µg/ml mAb. Representative results of two (A) and four (B) experiments performed with different donors (Mean {plus minus} SEM, *p<0.05, **p<0.05, Students t-test).
Supplementary Figure 3 from Retuning of Mouse NK Cells after Interference with MHC Class I Sensing Adjusts Self-Tolerance but Preserves Anticancer Response
Authors: Wagner Arnika Kathleen , Wickström Stina Linnea , Tallerico Rossana , Salam Sadia , Lakshmikanth Tadepally , Brauner Hanna , Höglund Petter , Carbone Ennio , Johansson Maria Helena , Kärre Klas
Published: April 2023

Supplementary Figure 3. In vivo receptor occupancy after monovalent 5E6 treatment.
Supplementary Figures S1 - S7, Table 1 from Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage
Authors: Medina-Echeverz José , Ma Chi , Duffy Austin G. , Eggert Tobias , Hawk Nga , Kleiner David E. , Korangy Firouzeh , Greten Tim F.
Published: April 2023

Supplementary Figure S1. Systemic agonistic anti-CD40 induces liver toxicity. Supplementary Figure S2. Systemic administration of anti-CD40 agonist enhances liver inflammation in a model of hepatic metastases. Supplementary Figure S3. Agonistic CD40 antibody induces CD11b+ Gr-1+ cell maturation in the liver. Supplementary Figure S4. Representative gating of CD40 and CD80 expression on tumor-induced hepatic CD11b+ Gr-1+ cells after agonist CD40 antibody injection. Supplementary Figure S5. Differential contribution of G-MDSC and MDSC subsets in agonistic CD40 antibody-mediated liver damage. Supplementary Figure S6. Purity and phenotype of tumor-induced hepatic CD11b+enriched cells used for congenic transfer experiments. Supplementary Figure S7. Human anti-CD40 antibody modulates arginase expression in human MDSC. Supplementary Table 1. List of patients.
Supplementary Figure S1 from Broadening Specificity and Enhancing Cytotoxicity of Adoptive T Cells for Nasopharyngeal Carcinoma Immunotherapy
Authors: Faè Damiana Antonia , Martorelli Debora , Mastorci Katy , Muraro Elena , Dal Col Jessica , Franchin Giovanni , Barzan Luigi , Comaro Elisa , Vaccher Emanuela , Rosato Antonio , Dolcetti Riccardo
Published: April 2023

Supplementary figure describing the generation of C666.1 NPC cell line stably espressing HLA-A02 and the induction of immunogenic cell death in LCLs derived from NPC patients.
Figure S1 from Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC
Authors: Brockwell Natasha K. , Owen Katie L. , Zanker Damien , Spurling Alex , Rautela Jai , Duivenvoorden Hendrika M. , Baschuk Nikola , Caramia Franco , Loi Sherene , Darcy Phillip K. , Lim Elgene , Parker Belinda S.
Published: April 2023

Varying doses of IFN treatment and PD-L1/IFNAR expression
Supplementary Figure S4 from Rescue of Tolerant CD8+ T Cells during Cancer Immunotherapy with IL2:Antibody Complexes
Authors: Klevorn Lauryn E. , Berrien-Elliott Melissa M. , Yuan Jinyun , Kuehm Lindsey M. , Felock Gregory D. , Crowe Sean A. , Teague Ryan M.
Published: April 2023

IL-2/JES6-5H4 complex selectively expands CD8+ T cells and NK cells
Supplementary Figure S2 from Rescue of Tolerant CD8+ T Cells during Cancer Immunotherapy with IL2:Antibody Complexes
Authors: Klevorn Lauryn E. , Berrien-Elliott Melissa M. , Yuan Jinyun , Kuehm Lindsey M. , Felock Gregory D. , Crowe Sean A. , Teague Ryan M.
Published: April 2023

Tbx21-/- T cells produce less IFNgamma after IL-2c treatment compared to WT
Supplementary Figure S5 from Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer
Authors: Bransi Ali , Salgado Oscar Camilo , Beffinger Michal , Milo Karim , Silina Karina , Yagita Hideo , Becher Burkhard , Knuth Alexander , van den Broek Maries
Published: April 2023

Immune interventions can shift the balance from tolerance into priming of tumor-specific immunity.
Supplementary Figure S3 from Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer
Authors: Bransi Ali , Salgado Oscar Camilo , Beffinger Michal , Milo Karim , Silina Karina , Yagita Hideo , Becher Burkhard , Knuth Alexander , van den Broek Maries
Published: April 2023

Prevention of tolerance by anti-CD40 + IL-2cx + IL-12Fc.
Supplementary Table S3 from Hypomethylation of the Treg-Specific Demethylated Region in FOXP3 Is a Hallmark of the Regulatory T-cell Subtype in Adult T-cell Leukemia
Authors: Shimazu Yayoi , Shimazu Yutaka , Hishizawa Masakatsu , Hamaguchi Masahide , Nagai Yuya , Sugino Noriko , Fujii Sumie , Kawahara Masahiro , Kadowaki Norimitsu , Nishikawa Hiroyoshi , Sakaguchi Shimon , Takaori-Kondo Akifumi
Published: April 2023

Supplementary Table S3. Female Patients' characteristics
Supplementary Table S2 from Hypomethylation of the Treg-Specific Demethylated Region in FOXP3 Is a Hallmark of the Regulatory T-cell Subtype in Adult T-cell Leukemia
Authors: Shimazu Yayoi , Shimazu Yutaka , Hishizawa Masakatsu , Hamaguchi Masahide , Nagai Yuya , Sugino Noriko , Fujii Sumie , Kawahara Masahiro , Kadowaki Norimitsu , Nishikawa Hiroyoshi , Sakaguchi Shimon , Takaori-Kondo Akifumi
Published: April 2023

Supplementary Table S2. The list of primers used for bisulfite-specific PCR and sequencing
Supplemental Methods and Figure Legends from BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma
Authors: Bradley Sherille D. , Chen Zeming , Melendez Brenda , Talukder Amjad , Khalili Jahan S. , Rodriguez-Cruz Tania , Liu Shujuan , Whittington Mayra , Deng Wanleng , Li Fenge , Bernatchez Chantale , Radvanyi Laszlo G. , Davies Michael A. , Hwu Patrick , Lizée Gregory
Published: April 2023

Supplemental Methods and Figure Legends
Supplementary Figures 1 through 7 and Supplementary Tables 1 through 3 from Tumor-Associated Monocytes/Macrophages Impair NK-Cell Function via TGFβ1 in Human Gastric Cancer
Authors: Peng Liu-sheng , Zhang Jin-yu , Teng Yong-sheng , Zhao Yong-liang , Wang Ting-ting , Mao Fang-yuan , Lv Yi-pin , Cheng Ping , Li Wen-hua , Chen Na , Duan Mubing , Chen Weisan , Guo Gang , Zou Quan-ming , Zhuang Yuan
Published: April 2023

Figure S1. NK cell and T cell numbers in the peripheral blood, non-tumor and tumor tissues of GC patients. Figure S2. Expression of activating and inhibitory receptors on NK cells in the peripheral blood, non-tumor and tumor tissues of GC patients. Figure S3. Expression of CD56 and CD16 on NK cells in the peripheral blood, non-tumor and tumor tissues of GC patients. Figure S4. The expression of HLA-DR on tissue-associated monocytes/macrophages in GC patients. Figure S5. The expression of CD48, PD-L1 and PD-L2 on tissue-associated monocytes/macrophages in GC patients. Figure S6. Co-expression of CD68 and TGF-beta1 in tumors of GC patients. Figure S7. Surface expression levels of TGF-beta1 on tumor-associated monocytes/macrophages in GC patients. Table S1. Clinical characteristics of 65 GC patients. Table S2. Fluorochrome-conjugated antibodies used in flow cytometry. Table S3. Univariate and multivariate analyses of factors associated with survival.
Supplemental Figure 2 from Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies
Authors: Hossain Fokhrul , Al-Khami Amir A. , Wyczechowska Dorota , Hernandez Claudia , Zheng Liqin , Reiss Krzystoff , Valle Luis Del , Trillo-Tinoco Jimena , Maj Tomasz , Zou Weiping , Rodriguez Paulo C. , Ochoa Augusto C.
Published: April 2023

Supplemental Figure 2: Etomoxir lowers CPT1 enzymatic activity but does not alter the generation of MDSC subsets, induce apoptosis, or affect proliferation in BM-MDSCs.
Supplementary Figure 4 from Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses
Authors: Kumai Takumi , Lee Sujin , Cho Hyun-Il , Sultan Hussein , Kobayashi Hiroya , Harabuchi Yasuaki , Celis Esteban
Published: April 2023

OX40 stimulation supports the survival of CD4 T cells, which received vaccine
Supplementary Figure 3 from Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses
Authors: Kumai Takumi , Lee Sujin , Cho Hyun-Il , Sultan Hussein , Kobayashi Hiroya , Harabuchi Yasuaki , Celis Esteban
Published: April 2023

TriVax/OX40 elicits endogenous CD4 T cell responses against a non-immunogenic tumor-associated antigen
Supplementary Fig. S7 from Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors
Authors: Manuel Edwin R. , Chen Jeremy , D'Apuzzo Massimo , Lampa Melanie G. , Kaltcheva Teodora I. , Thompson Curtis B. , Ludwig Thomas , Chung Vincent , Diamond Don J.
Published: April 2023

PMN tracking in control mice. (A) Normal C57BL/6 non-tumor bearing mice were injected intravenously with 50 uL of a 20 uM working solution of NS-NIR reagent. Mice were imaged 1 hr proceeding injection of NS-NIR. Mice were also injected with 300 ug D-luciferin in 200 ÂµL PBS 5 min prior to imaging. Image depicts representative mouse. Imaged with a Xenogen IVIS 100. (B) Mice treated with shScr-ST or shIDO-ST alone show no intratumoral PMN infiltration. C57BL/6 mice implanted with orthotopic KPC-luc tumors were treated with shIDO-ST or shScr-ST as outlined in Supplementary Fig. S2. Mice were imaged at the indicated time points following first treatment with ST. Imaged with a Xenogen IVIS 100. (C) Key replicate data of PMN infiltration (brown) and tumor (rainbow) for indicated treatment groups. Imaged with a Spectral Ami-X.
Supplementary Fig. S2 from Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors
Authors: Manuel Edwin R. , Chen Jeremy , D'Apuzzo Massimo , Lampa Melanie G. , Kaltcheva Teodora I. , Thompson Curtis B. , Ludwig Thomas , Chung Vincent , Diamond Don J.
Published: April 2023

Treatment dose and scheduling. (A) Doses and schedule of therapies administered to tumor bearing mice. (B) Control groups treated with gemcitabine alone and NAB alone. Mice were implanted with 5x105 KPC-luc cells on day 0 and treated as specified in (A). Images are representative mice for multiple experiments using identical treatment regimens.
Supplementary Figure S2 from Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus–Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma
Authors: Zheng Yong , Parsonage Greg , Zhuang Xiaodong , Machado Lee R. , James Christine H. , Salman Asmaa , Searle Peter F. , Hui Edwin P. , Chan Anthony T.C. , Lee Steven P.
Published: April 2023

Differentiation status of T cells from an NPC patient transduced with the coTCRcys receptor.
Supplementary Fig. S1 from Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors
Authors: Manuel Edwin R. , Chen Jeremy , D'Apuzzo Massimo , Lampa Melanie G. , Kaltcheva Teodora I. , Thompson Curtis B. , Ludwig Thomas , Chung Vincent , Diamond Don J.
Published: April 2023

Generation of KPC-luc orthotopic model. (A) 28 day orthotopic KPC tumor (top, 2050 mm3) extracted from untreated C57BL/6 mouse versus normal C57BL/6 pancreas (bottom, 84 mm3). (B) KPC-luc cell line incubated with increasing titration of D-luciferin and imaged using a Xenogen 100 IVIS (C) 5x105 KPC-luc cells were implanted into the pancreas of C57BL/6 mice and growth monitored for 21 days. Representative mouse shown. (D) Kaplan-Meier curve for mice (n=10) implanted with 5x105 KPC-luc cells.
Supplementary Material and Methods; Figure Legends from Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity
Authors: Bastid Jeremy , Regairaz Anne , Bonnefoy Nathalie , Déjou Cécile , Giustiniani Jérôme , Laheurte Caroline , Cochaud Stéphanie , Laprevotte Emilie , Funck-Brentano Elisa , Hemon Patrice , Gros Laurent , Bec Nicole , Larroque Christian , Alberici Gilles , Bensussan Armand , Eliaou Jean-François
Published: April 2023

Supplementary material and methods and supplementary figure legends.
Supplementary Figure 5 from Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity
Authors: Bastid Jeremy , Regairaz Anne , Bonnefoy Nathalie , Déjou Cécile , Giustiniani Jérôme , Laheurte Caroline , Cochaud Stéphanie , Laprevotte Emilie , Funck-Brentano Elisa , Hemon Patrice , Gros Laurent , Bec Nicole , Larroque Christian , Alberici Gilles , Bensussan Armand , Eliaou Jean-François
Published: April 2023

CD39 ATPase activity can be assessed by measuring exogenous ATP consumption or phosphate release.
Supplementary Figure 4 from Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity
Authors: Bastid Jeremy , Regairaz Anne , Bonnefoy Nathalie , Déjou Cécile , Giustiniani Jérôme , Laheurte Caroline , Cochaud Stéphanie , Laprevotte Emilie , Funck-Brentano Elisa , Hemon Patrice , Gros Laurent , Bec Nicole , Larroque Christian , Alberici Gilles , Bensussan Armand , Eliaou Jean-François
Published: April 2023

Representative IHC staining of CD39 expression in human normal and tumor tissues (clone HPA014067).
Supplementary Table 3 from Reprogramming Tumor-Infiltrating Dendritic Cells for CD103+CD8+ Mucosal T-cell Differentiation and Breast Cancer Rejection
Authors: Wu Te-Chia , Xu Kangling , Banchereau Romain , Marches Florentina , Yu Chun I. , Martinek Jan , Anguiano Esperanza , Pedroza-Gonzalez Alexander , Snipes G. Jackson , O'Shaughnessy Joyce , Nishimura Stephen , Liu Yong-Jun , Pascual Virginia , Banchereau Jacques , Oh Sangkon , Palucka Karolina
Published: April 2023

PDF file - PDF file, Supplementary Table 3. PALO_0.01_TTest_0.05_1.5xUp in PMB + Curdlan vs CTL.
Supplementary Table 2 from Reprogramming Tumor-Infiltrating Dendritic Cells for CD103+CD8+ Mucosal T-cell Differentiation and Breast Cancer Rejection
Authors: Wu Te-Chia , Xu Kangling , Banchereau Romain , Marches Florentina , Yu Chun I. , Martinek Jan , Anguiano Esperanza , Pedroza-Gonzalez Alexander , Snipes G. Jackson , O'Shaughnessy Joyce , Nishimura Stephen , Liu Yong-Jun , Pascual Virginia , Banchereau Jacques , Oh Sangkon , Palucka Karolina
Published: April 2023

PDF file - 35K, Breast cancer cell lines were characterized which were based on original tissue, histopathological diagnosis and the receptor status (progesterone receptor, estrogen receptor, Her-2 and Insulin-like Growth Factor I Receptor).
Supplementary Figure 2 from Immunotherapy against Metastatic Melanoma with Human iPS Cell–Derived Myeloid Cell Lines Producing Type I Interferons
Authors: Miyashita Azusa , Fukushima Satoshi , Nakahara Satoshi , Kubo Yosuke , Tokuzumi Aki , Yamashita Junji , Aoi Jun , Haruta Miwa , Senju Satoru , Nishimura Yasuharu , Jinnin Masatoshi , Ihn Hironobu
Published: April 2023

We observed malignant tumor development from human iPS-ML-IFN cells in SCID mice for up to 12 weeks. During the observation period, the mice were healthy, and no significant difference was observed in the body weight of human iPS-ML-IFN-injected mice and control mice. (2A). Twelve weeks after the injection of human iPS-ML-IFN cells, the mice were sacrificed, and examined under a stereomicroscope. We found no differences in the organs including lung, spleen, liver and greater omentum between human iPS-ML-IFN-injected mice and control mice. (2B)
Supplementary Figure 1 from Sustained Complete Response to CTLA-4 Blockade in a Patient with Metastatic, Castration-Resistant Prostate Cancer
Authors: Graff Julie N. , Puri Sachin , Bifulco Carlo B. , Fox Bernard A. , Beer Tomasz M.
Published: April 2023

PDF file - 103K, Supplemental Figure 1. Frequency of HIBCH alteration across different studies available on cBioPortal for Cancer Genomics (http://www.cbioportal.org/public-portal/cross_cancer.do?).
Supplementary Figure Legends from Efficient Induction of Antitumor Immunity by Synthetic Toll-like Receptor Ligand–Peptide Conjugates
Authors: Zom Gijs G. , Khan Selina , Britten Cedrik M. , Sommandas Vinod , Camps Marcel G.M. , Loof Nikki M. , Budden Christina F. , Meeuwenoord Nico J. , Filippov Dmitri V. , van der Marel Gijsbert A. , Overkleeft Hermen S. , Melief Cornelis J.M. , Ossendorp Ferry
Published: April 2023

PDF file - 89K
Supplementary Table S1 from Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness
Authors: Miller Lance D. , Chou Jeff A. , Black Michael A. , Print Cristin , Chifman Julia , Alistar Angela , Putti Thomas , Zhou Xiaobo , Bedognetti Davide , Hendrickx Wouter , Pullikuth Ashok , Rennhack Jonathan , Andrechek Eran R. , Demaria Sandra , Wang Ena , Marincola Francesco M.
Published: April 2023

Clinical characteristics of the breast cancer cohorts.
Supplementary Figure S4 from Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness
Authors: Miller Lance D. , Chou Jeff A. , Black Michael A. , Print Cristin , Chifman Julia , Alistar Angela , Putti Thomas , Zhou Xiaobo , Bedognetti Davide , Hendrickx Wouter , Pullikuth Ashok , Rennhack Jonathan , Andrechek Eran R. , Demaria Sandra , Wang Ena , Marincola Francesco M.
Published: April 2023

Subgroup analysis in IBE and IBD tumors. Kaplan-Meier plots comparing the probability of DMFS of patients classified as FID, WID and PID.
Supplementary Movie 2 from αβ TCR-Mediated Recognition: Relevance to Tumor-Antigen Discovery and Cancer Immunotherapy
Authors: Reinherz Ellis L.
Published: April 2023

Supplementary Movie 2. This is an artist's rendition of what happens to the TCR complex (bottom) when a T cell moves from right to left and is ligated by pMHC (orange) on the stationary APC (top). Colors are as in Fig. 2 with the Cbeta FG loop noted. Movement of the TCR alpha-beta heterodimer relative to the squat CD3 heterodimers is evident as is force transmitted to the latter leading to signaling downstream (the light). Signaling results in subsequent integrin activation and cessation of cell movement.
Supplementary Figure S1 from Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness
Authors: Miller Lance D. , Chou Jeff A. , Black Michael A. , Print Cristin , Chifman Julia , Alistar Angela , Putti Thomas , Zhou Xiaobo , Bedognetti Davide , Hendrickx Wouter , Pullikuth Ashok , Rennhack Jonathan , Andrechek Eran R. , Demaria Sandra , Wang Ena , Marincola Francesco M.
Published: April 2023

The B/P, T/NK and M/D immune metagenes are coordinately expressed in breast tumors and leukocytes but not in breast cancer cell lines.
Supplementary Figure 3 from Episomal Expression of Truncated Listeriolysin O in LmddA-LLO–E7 Vaccine Enhances Antitumor Efficacy by Preferentially Inducing Expansions of CD4+FoxP3− and CD8+ T Cells
Authors: Chen Zhisong , Ozbun Laurent , Chong Namju , Wallecha Anu , Berzofsky Jay A. , Khleif Samir N.
Published: April 2023

PDF file - 2785K, Figure S3. LmddA does not augment Lm-E7 antitumor activity.
Supplementary Figure 2 from Episomal Expression of Truncated Listeriolysin O in LmddA-LLO–E7 Vaccine Enhances Antitumor Efficacy by Preferentially Inducing Expansions of CD4+FoxP3− and CD8+ T Cells
Authors: Chen Zhisong , Ozbun Laurent , Chong Namju , Wallecha Anu , Berzofsky Jay A. , Khleif Samir N.
Published: April 2023

PDF file - 6597K, Figure S2. LmddA-LLO-E7 and Lm-E7 induce similar E7-specific CD8+ T-cell response.
Supplementary Figures 1 - 6 from STAT3 in CD8+ T Cells Inhibits Their Tumor Accumulation by Downregulating CXCR3/CXCL10 Axis
Authors: Yue Chanyu , Shen Shudan , Deng Jiehui , Priceman Saul J. , Li Wenzhao , Huang Austin , Yu Hua
Published: April 2023

Supplemental Figure 1. Loss of Stat3 expression did not change IFN-induced chemokine levels in tumors. Supplemental Figure 2. Tumor infiltrating macrophages are expressing CXCL10. Supplemental Figure 3. Ablating Stat3 resulted no significant change in CXCR3 levels in CD8+ T cells from TDLN. Supplemental Figure 4. Blockade of IFNγ in tumors leads to significant reduction of tumor infiltrating IFNγ-expression CD8+ T cells in absence of Stat3 expression. Supplemental Figure 5. CXCL10 induced CD8+ T cell migration depends on Rho signaling but independent of Cdc42 and Rac1 signaling. Supplemental Figure 6. Illustration of STAT3 signaling in regulating CD8+ T cells migration toward tumors in an IFNγ/CXCL10/CXCR3-dependent manner.
Supplementary Figure 1 from Episomal Expression of Truncated Listeriolysin O in LmddA-LLO–E7 Vaccine Enhances Antitumor Efficacy by Preferentially Inducing Expansions of CD4+FoxP3− and CD8+ T Cells
Authors: Chen Zhisong , Ozbun Laurent , Chong Namju , Wallecha Anu , Berzofsky Jay A. , Khleif Samir N.
Published: April 2023

PDF file - 312K, Figure S1. LmddA-LLO-E7 induces regression of established TC-1 tumors.
Supplementary Figures 1 - 2 from STING Contributes to Antiglioma Immunity via Triggering Type I IFN Signals in the Tumor Microenvironment
Authors: Ohkuri Takayuki , Ghosh Arundhati , Kosaka Akemi , Zhu Jianzhong , Ikeura Maki , David Michael , Watkins Simon C. , Sarkar Saumendra N. , Okada Hideho
Published: April 2023

Supplementary Figure 1. Induction profiles of various known DNA sensors and adaptors in the glioma microenvoironment. Supplementary Figure 2. STING agonist promotes type-I IFN signaling in BILs.
Supplementary Figure S3 from Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells
Authors: Berger Carolina , Sommermeyer Daniel , Hudecek Michael , Berger Michael , Balakrishnan Ashwini , Paszkiewicz Paulina J. , Kosasih Paula L. , Rader Christoph , Riddell Stanley R.
Published: April 2023

Gating strategy for ROR1-expressing B cells in the lymph node.
Supplementary Figure S2 from Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells
Authors: Berger Carolina , Sommermeyer Daniel , Hudecek Michael , Berger Michael , Balakrishnan Ashwini , Paszkiewicz Paulina J. , Kosasih Paula L. , Rader Christoph , Riddell Stanley R.
Published: April 2023

Gating strategy for ROR1-expressing B cells in the bone marrow.
Supplementary Table 1 from Lack of STAT6 Attenuates Inflammation and Drives Protection against Early Steps of Colitis-Associated Colon Cancer
Authors: Leon-Cabrera Sonia A. , Molina-Guzman Emmanuel , Delgado-Ramirez Yael G. , Vázquez-Sandoval Armando , Ledesma-Soto Yadira , Pérez-Plasencia Carlos G. , Chirino Yolanda I. , Delgado-Buenrostro Norma L. , Rodríguez-Sosa Miriam , Vaca-Paniagua Felipe , Ávila-Moreno Federico , Gutierrez-Cirlos Emma B. , Arias-Romero Luis E. , Terrazas Luis I.
Published: April 2023

Data about primers used for RT-PCR analysis, including number of cycles and melting temperature
Supplemental Figure 4 from Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations
Authors: Sanders Kiah L. , Fox Barbara A. , Bzik David J.
Published: April 2023

MyD88 signalling requirement for survival.
Supplemental Figure 2 from Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations
Authors: Sanders Kiah L. , Fox Barbara A. , Bzik David J.
Published: April 2023

Distal presence of CPS and FACS data for CD80/86 activation.
Supplemental Table 8 from Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance
Authors: Doedens Andrew L. , Rubinstein Mark P. , Gross Emilie T. , Best J. Adam , Craig David H. , Baker Megan K. , Cole David J. , Bui Jack D. , Goldrath Ananda W.
Published: April 2023

Selected phosphatases up-regulated in PyMT tumor CD8+ T cells.
Supplemental Figure 1 from Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations
Authors: Sanders Kiah L. , Fox Barbara A. , Bzik David J.
Published: April 2023

Systemic myeloid cell numbers.
Supplemental Table 7 from Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance
Authors: Doedens Andrew L. , Rubinstein Mark P. , Gross Emilie T. , Best J. Adam , Craig David H. , Baker Megan K. , Cole David J. , Bui Jack D. , Goldrath Ananda W.
Published: April 2023

Transcripts down-regulated {greater than or equal to}2-fold in PyMT tumor versus splenic CD8+ T cells.
Supplemental Table 2 from Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance
Authors: Doedens Andrew L. , Rubinstein Mark P. , Gross Emilie T. , Best J. Adam , Craig David H. , Baker Megan K. , Cole David J. , Bui Jack D. , Goldrath Ananda W.
Published: April 2023

PyMT tumor CD8+ versus day 1 effector OT-I gene expression and fold change.
Supplemental Figure S5 from Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression
Authors: van der Sluis Tetje C. , Sluijter Marjolein , van Duikeren Suzanne , West Brian L. , Melief Cornelis J.M. , Arens Ramon , van der Burg Sjoerd H. , van Hall Thorbald
Published: April 2023

Mean tumor sizes and SEM of living animals are depicted for three groups: untreated (n=4), SLP vaccinated (peptide) (n=8) and SLP vaccination in the presence of PLX5622 (peptide + PLX) (n=8).
Supplemental Figure S4 from Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression
Authors: van der Sluis Tetje C. , Sluijter Marjolein , van Duikeren Suzanne , West Brian L. , Melief Cornelis J.M. , Arens Ramon , van der Burg Sjoerd H. , van Hall Thorbald
Published: April 2023

The percentage of antigen specific and IFN-γ producing CD8 T cells in (A-B) blood and (C) lymph nodes of non-tumor-bearing mice on (A) day 7 and (B) day 15 after vaccination, as analysed by flow cytometry. Values of vaccinated groups with control- or PLX3397 chow were not significantly different (as analysed by Student T test, P > 0.05).
Supplemental Figures 1-11 from Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance
Authors: Doedens Andrew L. , Rubinstein Mark P. , Gross Emilie T. , Best J. Adam , Craig David H. , Baker Megan K. , Cole David J. , Bui Jack D. , Goldrath Ananda W.
Published: April 2023

Supplemental Figure 1: Five day IL-15cx treatment results in splenic CD8+ T cell activation and up-regulation of cytotoxic molecule expression in PyMT tumor-bearing mice. Supplemental Figure 2: PyMT tumor single-cell suspensions induce IL-2 / IL-15 resistance in CD8+ T cells. Supplemental Figure 3: Abundance of IL-2 / IL-15 cytokine receptor chains in PyMT tumor, acute/persistent infection, and TRM CD8+ T cells. Supplemental Figure 4: Gene expression in tumor versus acute infection CD8+ T cells. Supplemental Figure 5: Differentially-regulated transcripts in PyMT tumor CD8+ T cells versus naive, early effector, peak effector and memory T cells. Supplemental Figure 6: Human breast cancer CD8+ T cell infiltrate. Supplemental Figure 7: TRM "core signature" gene expression and transcriptional regulator TOX correlation with IL-15 resistance. Supplemental Figure 8: IL-15cx treatment of persistent virus-infected mice results in decreased relative abundance of exhausted antigen-specific CD8+ T cells. Supplemental Figure 9: Combined in vivo IL-15cx and αPD-L1 antibody treatment does not rescue PyMT CD8+ T cell cytokine non-responsiveness. Supplemental Figure 10: Expression of CD80 and CD200R on CD8+ T cells from PyMT tumor and persistent viral infection. Supplemental Figure 11: Activated and expanded tumor-specific CD8+ T cells adoptively transferred to tumor-bearing mice localize to tumor, but rapidly up-regulate PD-1 and CD244.
Supplementary Figures 1 through 10 from Preserved Activity of CD20-Specific Chimeric Antigen Receptor–Expressing T Cells in the Presence of Rituximab
Authors: Rufener Gregory A. , Press Oliver W. , Olsen Philip , Lee Sang Yun , Jensen Michael C. , Gopal Ajay K. , Pender Barbara , Budde Lihua E. , Rossow Jeffrey K. , Green Damian J. , Maloney David G. , Riddell Stanley R. , Till Brian G.
Published: April 2023

Supplemental Figure S1. (A) Schematic diagrams of CD20-specific CAR constructs. (B) Representative histogram of CAR expression. Supplemental Figure S2. (A) Gating strategy for analyzing proliferation of CFSE-stained T cells. (B) Histograms of CFSE dilution of CD3+ T cells corresponding to the experiment in Figure 2. Supplemental Figure S3. Proliferation and cytokine secretion of 1F5-28-BB-z CAR. Supplemental Figure S4. Proliferation, cytokine secretion, and cytotoxicity of CAR T cells with fully human anti-CD20 scFv. Supplemental Figure S5. CD20 expression of K80-20low, K80-20med, K80-20high as determined by flow cytometry. Supplemental Figure S6. The absolute cytokine concentrations from T cell supernatants from the experiment in Figure 4 are shown. Supplemental Figure S7. Rituximab-refractory Raji-ffLuc have the same CD20 expression as parental Raji-ffLuc cells. Supplemental Figure S8. (A) Individual mouse bioluminescent tumor burden traces over time corresponding to Figure 5. (B) Representative mouse bioluminescence images. Supplemental Figure S9. Presence of circulating T cells in mice. Supplemental Figure S10. Ofatumumab blocks antigen binding of Ab used to derive CAR scFv.
Supplementary Figure Legend from Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
Authors: Cooper Zachary A. , Juneja Vikram R. , Sage Peter T. , Frederick Dennie T. , Piris Adriano , Mitra Devarati , Lo Jennifer A. , Hodi F. Stephen , Freeman Gordon J. , Bosenberg Marcus W. , McMahon Martin , Flaherty Keith T. , Fisher David E. , Sharpe Arlene H. , Wargo Jennifer A.
Published: April 2023

Supplementary Figure Legend
Supplemental Methods, Tables 1 - 2, from PolyI:C–Induced, TLR3/RIP3-Dependent Necroptosis Backs Up Immune Effector–Mediated Tumor Elimination In Vivo
Authors: Takemura Ryo , Takaki Hiromi , Okada Seiji , Shime Hiroaki , Akazawa Takashi , Oshiumi Hiroyuki , Matsumoto Misako , Teshima Takanori , Seya Tsukasa
Published: April 2023

Supplemental Table 1. Sequences of primers. Supplemental Table 2. Percentage of cell viability. Supplemental Figure 1. Caspase-11 expression and IL-1B production. Supplemental Figure 2. TLR4 expression in CT26 cells. Supplemental Figure 3. RIP3 overexpression in B16D8. Supplemental Figure 4. Expression level of cIAP1, cIAP2, cFLIPS and cFLIPL mRNA in CT26 cells. Supplemental Figure 5. DCs did not exhibit cytotoxicity against CT26 cells. Supplemental Figure 6. TUNEL stain in tumor tissues prepared from CT26 bearing Rag2-/-/Jak3-/- mice.
Supplementary Table 5 from The Tumor Microenvironment Shapes Lineage, Transcriptional, and Functional Diversity of Infiltrating Myeloid Cells
Authors: Elpek Kutlu G. , Cremasco Viviana , Shen Hua , Harvey Christopher J. , Wucherpfennig Kai W. , Goldstein Daniel R. , Monach Paul A. , Turley Shannon J.
Published: April 2023

XLSX file - 2K, Supplementary Table S5: Expression values for PPARa-associated genes from the heatmap in Figure 6C.
Supplementary Table 3 from The Tumor Microenvironment Shapes Lineage, Transcriptional, and Functional Diversity of Infiltrating Myeloid Cells
Authors: Elpek Kutlu G. , Cremasco Viviana , Shen Hua , Harvey Christopher J. , Wucherpfennig Kai W. , Goldstein Daniel R. , Monach Paul A. , Turley Shannon J.
Published: April 2023

XLSX file - 12K, Supplementary Table S3: Expression values for neutrophil-associated genes from the heatmap in Figure 5B.
Supplementary Table 2 from The Tumor Microenvironment Shapes Lineage, Transcriptional, and Functional Diversity of Infiltrating Myeloid Cells
Authors: Elpek Kutlu G. , Cremasco Viviana , Shen Hua , Harvey Christopher J. , Wucherpfennig Kai W. , Goldstein Daniel R. , Monach Paul A. , Turley Shannon J.
Published: April 2023

XLSX file - 7K, Supplementary Table S2: Expression values for hypoxia-related genes from the heatmap in Figure 4D.
Figure S1 from Immune Cell Gene Signatures for Profiling the Microenvironment of Solid Tumors
Authors: Nirmal Ajit J. , Regan Tim , Shih Barbara B. , Hume David A. , Sims Andrew H. , Freeman Tom C.
Published: April 2023

Supplementary Figure 1
Supplemental Figure S5 from Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas
Authors: Long Adrienne H. , Highfill Steven L. , Cui Yongzhi , Smith Jillian P. , Walker Alec J. , Ramakrishna Sneha , El-Etriby Rana , Galli Susana , Tsokos Maria G. , Orentas Rimas J. , Mackall Crystal L.
Published: April 2023

ATRA treatment of 143b osteosarcoma cells does not change GD2 expression.
Supplemental Figure S3 from Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas
Authors: Long Adrienne H. , Highfill Steven L. , Cui Yongzhi , Smith Jillian P. , Walker Alec J. , Ramakrishna Sneha , El-Etriby Rana , Galli Susana , Tsokos Maria G. , Orentas Rimas J. , Mackall Crystal L.
Published: April 2023

Increased number of MDSCs present in sarcoma tumor-bearing mice, but not in neuroblastoma tumor-bearing mice.
Supplemental Figure S2 from Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas
Authors: Long Adrienne H. , Highfill Steven L. , Cui Yongzhi , Smith Jillian P. , Walker Alec J. , Ramakrishna Sneha , El-Etriby Rana , Galli Susana , Tsokos Maria G. , Orentas Rimas J. , Mackall Crystal L.
Published: April 2023

EW8 Ewing sarcoma also induces MDSCs in NSG mice that can be modulated with ATRA to improve efficacy of GD2-CAR T cell therapies.
Supplemental Figure S1 from Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas
Authors: Long Adrienne H. , Highfill Steven L. , Cui Yongzhi , Smith Jillian P. , Walker Alec J. , Ramakrishna Sneha , El-Etriby Rana , Galli Susana , Tsokos Maria G. , Orentas Rimas J. , Mackall Crystal L.
Published: April 2023

GD2-CAR T cells specifically lyse GD2+ tumor cells in vitro.
Supplementary Table 3 from IL32 Is Progressively Expressed in Mycosis Fungoides Independent of Helper T-cell 2 and Helper T-cell 9 Polarization
Authors: Ohmatsu Hanako , Humme Daniel , Gulati Nicholas , Gonzalez Juana , Möbs Markus , Suárez-Fariñas Mayte , Cardinale Irma , Mitsui Hiroshi , Guttman-Yassky Emma , Sterry Wolfram , Krueger James G.
Published: April 2023

PDF file - 53K, Selected upregulated canonical Pathways in IL-32 treated MyLa cells.
Supplementary Figure Legends from Mechanisms That Can Promote Peripheral B-cell Lymphoma in ATM-Deficient Mice
Authors: Tepsuporn Suprawee , Hu Jiazhi , Gostissa Monica , Alt Frederick W.
Published: April 2023

PDF file - 199K
Figure S1 from IL15 Infusion of Cancer Patients Expands the Subpopulation of Cytotoxic CD56bright NK Cells and Increases NK-Cell Cytokine Release Capabilities
Authors: Dubois Sigrid , Conlon Kevin C. , Müller Jürgen R. , Hsu-Albert Jennifer , Beltran Nancy , Bryant Bonita R. , Waldmann Thomas A.
Published: April 2023

Differentiation from CD56 bright to CD56 dim /CD94 high to CD56 dim /CD94 low NK cells is accompanied by increasing requirements for IL-15 to induce their proliferation. Various NK cell subsets were sorted from PBMCs of normal donors, CFSE-labeled, cultured for 7 days, and their CFSE dilu- tion as a measure of proliferation was determined by FACS.
Supplementary Figure 1 from The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity
Authors: Hudecek Michael , Sommermeyer Daniel , Kosasih Paula L. , Silva-Benedict Anne , Liu Lingfeng , Rader Christoph , Jensen Michael C. , Riddell Stanley R.
Published: April 2023

(A) Mice were inoculated with 0.5 million Raji-ffluc cells via tail vein injection and tumor engraftment was confirmed by bioluminescence imaging on day six. On day seven, mice received a single i.v. injection of various doses of CD8+ TCM-derived T-cells transduced with the short spacer CD19/4-1BB/CD3ζ-CAR or of control T-cells (EGFRt). (B) Tumor growth was measured by bioluminescence imaging and is plotted for individual mice (4 mice per group). Arrows mark the day of T-cell transfer. Bioluminescence images from day six (one day before T-cell transfer) and day 19 (12 days after transfer) are shown.
Supplemental Figure 4 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination
Authors: Gibson Heather M. , Veenstra Jesse J. , Jones Richard , Vaishampayan Ulka , Sauerbrey Michele , Bepler Gerold , Lum Lawrence , Reyes Joyce , Weise Amy , Wei Wei-Zen
Published: April 2023

Q141K substitution in feline HER2.
Supplemental Figure 3 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination
Authors: Gibson Heather M. , Veenstra Jesse J. , Jones Richard , Vaishampayan Ulka , Sauerbrey Michele , Bepler Gerold , Lum Lawrence , Reyes Joyce , Weise Amy , Wei Wei-Zen
Published: April 2023

Sequence alignment of HER2 extracellular and transmembrane regions (ECTM) from 5 mammalian species.
Supplementary Tables S1 through S9 from Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells
Authors: Ohue Yoshihiro , Kurose Koji , Nozawa Ryohei , Isobe Midori , Nishio Yumi , Tanaka Tomonori , Doki Yoshinori , Hori Takashi , Fukuoka Junya , Oka Mikio , Nakayama Eiichi
Published: April 2023

Table S1 and Table S2- Patients' characteristics. Table S3 - Cell lines. Table S4 - Antibodies used. Table S5 - Expression of PD-L1 and Galectin-9 in lung cancer. Table S6 - Expression of XAGE1 in lung cancer. Table S7 - Cut-off values for each T-cell parameter. Table S8 - Standardized coefficients in discriminant functions. Table S9 - Univariate and multivariate analysis.
Supplementary Figure S1 from Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20
Authors: Weiskopf Kipp , Anderson Katie L. , Ito Daisuke , Schnorr Peter J. , Tomiyasu Hirotaka , Ring Aaron M. , Bloink Kristin , Efe Jem , Rue Sarah , Lowery David , Barkal Amira , Prohaska Susan , McKenna Kelly M. , Cornax Ingrid , O'Brien Timothy D. , O'Sullivan M. Gerard , Weissman Irving L. , Modiano Jaime F.
Published: April 2023

Recombinant production and evaluation of canine SIRPalpha protein.
Supplementary Tables 1 - 3 from PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection
Authors: MacFarlane Alexander W. , Jillab Mowafaq , Plimack Elizabeth R. , Hudes Gary R. , Uzzo Robert G. , Litwin Samuel , Dulaimi Essel , Al-Saleem Tahseen , Campbell Kerry S.
Published: April 2023

PDF file - 79K, Supplemental Table S1. Donor Characteristics. Supplemental Table S2. Antibody staining panel. Supplemental Table S3. Specific immune parameters analyzed.
Supplementary Figure 3 from Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
Authors: da Silva Ines Pires , Gallois Anne , Jimenez-Baranda Sonia , Khan Shaukat , Anderson Ana C. , Kuchroo Vijay K. , Osman Iman , Bhardwaj Nina
Published: April 2023

PDF file - 72K, Fig. S3. MD NK cells are functionally impaired/exhausted.
Supplementary Figure 1 from Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
Authors: da Silva Ines Pires , Gallois Anne , Jimenez-Baranda Sonia , Khan Shaukat , Anderson Ana C. , Kuchroo Vijay K. , Osman Iman , Bhardwaj Nina
Published: April 2023

PDF file - 172K, Fig. S1. NK cells from melanoma patients up-regulate inhibitory receptors and down-regulate activating receptors.
Supplementary Figure 2 from PD-1 Suppresses Development of Humoral Responses That Protect against Tn-Bearing Tumors
Authors: Haro Marcela A. , Littrell Chad A. , Yin Zhaojun , Huang Xuefei , Haas Karen M.
Published: April 2023

Figure S2. Survival in PD-1-/- mice following primary and secondary tumor challenge
Supplementary Figure 2 from Virotherapy with a Semliki Forest Virus–Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade
Authors: Quetglas José I. , Labiano Sara , Aznar M. Ángela , Bolaños Elixabet , Azpilikueta Arantza , Rodriguez Inmaculada , Casales Erkuden , Sánchez-Paulete Alfonso R. , Segura Víctor , Smerdou Cristian , Melero Ignacio
Published: April 2023

Supplementary figure 2. Effects of treatment with SFV-IL12 + anti-PD-1 combination on the B16.F10 and 4T1 tumor models.
Supplementary Figure Legends from Post-Sepsis State Induces Tumor-Associated Macrophage Accumulation through CXCR4/CXCL12 and Favors Tumor Progression in Mice
Authors: Mota José M. , Leite Caio A. , Souza Lucas E. , Melo Paulo H. , Nascimento Daniele C. , de-Deus-Wagatsuma Virginia M. , Temporal Jessica , Figueiredo Florêncio , Noushmehr Houtan , Alves-Filho José C. , Cunha Fernando Q. , Rego Eduardo M.
Published: April 2023

Suplementary Figure Legends
Supplementary Figure 1 from Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells
Authors: Homet Moreno Blanca , Zaretsky Jesse M. , Garcia-Diaz Angel , Tsoi Jennifer , Parisi Giulia , Robert Lidia , Meeth Katrina , Ndoye Abibatou , Bosenberg Marcus , Weeraratna Ashani T. , Graeber Thomas G. , Comin-Anduix Begoña , Hu-Lieskovan Siwen , Ribas Antoni
Published: April 2023

IGV plot exome sequencing from YUMM1.1, YUMM1.7 and YUMM2.1, tumor growth curve of YUMM1.7 and B16 with 4 mice in each group, analysis of the non-synonymous mutational load compared to a strain-matched normal with known dbSNP variants excluded.
Supplementary Figures 1 through 6 and Supplementary Table 1 from Synergistic COX2 Induction by IFNγ and TNFα Self-Limits Type-1 Immunity in the Human Tumor Microenvironment
Authors: Wong Jeffrey L. , Obermajer Nataša , Odunsi Kunle , Edwards Robert P. , Kalinski Pawel
Published: April 2023

Supplemental Table 1 provides the information about the clinical status of patients(donors of ovarian cancer ascites). Supplemental Figures S1-S6 provide the characterization of the immune cells and experimental systems involved in the study and additional data from complementary assays and individual donors. Figure legends are provided under each Figure.